Delayed gastrointestinal recovery after abdominal operation - role of alvimopan.

A single trial demonstrated a nonsignificant trend toward more cardiac-related adverse events. 18 As a result of the POI trials and demonstration of safety, the US Food and Drug Administration (FDA), approved alvimopan in 2008 for the treatment of POI, with ongoing evaluation to ensure continued benefit.

also in 5,406 other papers